VRDN
NASD Viridian Therapeutics, Inc.$19.40 ↑ +0.00 (+0.00%) Trading Up from the previous close of $19.40, $0.15 below the day’s high of $19.55
- YTD change
- -37.66%
- vs 20-day SMA
- -10.21%
- vs 200-day SMA
- -15.28%
Price ranges
Price & Performance
+5.50 (+39.57%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 50.3% away from all-time highs of $39.00
- VRDN is down 38% since the beginning of the year
- VRDN is down 9% over the past 12 months
- VRDN is down 15% over the past 1 month
- 17% of all VRDN investors are betting against VRDN
VRDN reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -6.9%.
- Previous minute
- +$0.00
- Last hour
- -$0.01
- Last 5 days
- -6.10%
- vs 8-day SMA
- -5.84%
No alerts for VRDN in the last day.
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
